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Non-small cell lung cancer (NSCLC) is a malignant tumour with
poor prognosis, and the postoperative survival is not satisfactory
(Mountain, 1997). Although adjuvant therapy was introduced to
improve the postoperative prognosis, it has been concluded that
radiotherapy can not improve the survival although it can reduce
the local recurrence rate. Therefore, systemic chemotherapy has
been expected to improve the postoperative survival by suppress-
ing occurrence of distant metastasis, and a variety of chemothe-
rapeutic regimens have been attempted. However, the efficacy of
postoperative adjuvant chemotherapy has not been established yet
(Ihde et al, 1994). 
However, a recent retrospective study conducted by Kyoto
University suggested that UFT administration was effective as a
postoperative adjuvant therapy for NSCLC (Tanaka et al, 1998a).
UFT is an oral 5-fluorouracil (5-FU) derivative drug composed of
tegafur (1-[2-tetrahydrofuryl]-5-fluoroiracil, FT) and uraci (U);
tegafur is a pro-drug that persistently releases 5-FU, and uracil is
added to inhibit degradation of the released 5-FU (Fujii et al, 1978;
Ikenaka et al, 1979). As a result, when UFT is administrated,
certain 5-FU concentration in blood and tumour tissues can be
maintained for a long time. The efficacy of postoperative oral
administration of UFT was confirmed by a prospective random-
ized study conducted by ‘The West Japan Study Group for lung
cancer surgery’; 5-year survival rates of pathologic (p-) stage I–III,
NSCLC were 64.1%, 60.6% and 49.0% in patients who received
postoperative UFT administration (400 mg body21 day21 for one
year after surgery, UFT group), in those who received the same
UFT administration following intravenous infusion of CDDP
(50 mg/m2 body surface for one course) + VDS (2–3 mg kg body
weight21 for 3 courses) (CVUft group), and in those who received
no adjuvant therapy (Control group), respectively (P = 0.044
among 3 groups, and P = 0.019 between the UFT group and the
Control group) (Wada et al, 1996). The efficacy of postoperative
UFT administration in NSCLC was demonstrated in other
prospective randomized studies (The Study Group of Adjuvant
Chemotherapy for Lung Cancer (Chubu, Japan), 1995; Wada et al,
1999). Although these results suggest the efficacy of postoperative
UFT administration, postoperative recurrence may appear in some
cases even if UFT administration is performed. Thus, if whether
UFT administration is effective or not can be predicted in an indi-
vidual patient before the administration, postoperative prognosis
can be improved when efficacy of UFT administration is expected,
and medical and financial disadvantage of UFT administration can
be relieved when the efficacy is not expected. 
The p53 tumour suppressor gene protects the genome against a
variety of damages, and suppresses occurrence of malignant
tumour (Levine et al, 1991). The p53 gene induces apoptosis as
well as regulates the cell cycle (Clarke et al, 1993; Lowe et al,
1993). Apoptosis is a kind of cell death distinct from necrosis,
showing morphological features such as cell shrinkage, loss of
cell–cell contact, chromatin condensation and intranucleosomal
degradation of DNA (Kerr et al, 1972). Apoptosis is an essential
phenomenon for normal development and maintenance of home-
ostasis, and also plays an important role in suppressing prolifera-
tion of malignant tumour cells (Symonds et al, 1994; Holmgren
et al, 1995). It is known that apoptosis is induced by various
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that sensitivity to anticancer agents and radiotherapy can be
influenced by the status of some genes associated with apoptosis
such as the p53 gene (Clarke et al, 1993; Lowe et al, 1993). 
In a preliminary study, we have already reported that the effi-
cacy of oral administration of FT and UFT after surgery for
NSCLC may be influenced by p53 status (Tanaka et al, 1999a).
Moreover, we have already reported that balance between incid-
ence apoptotic cell death and tumour-cell proliferation is an
important factor to predict postoperative survival in resected
NSCLC (Tanaka et al, 1999b). In the present study, whether the
efficacy of postoperative UFT administration was influenced by
incidence of apoptosis (apoptotic index: AI) and by status of p53
and  bcl-2 regulating apoptosis in more homogeneous patients 
(p-stage I patients) was examined. 
PATIENTS AND METHODS 
A total of 163 consecutive patients with p-stage I, NSCLC who
underwent complete tumour resection and mediastinal lymph node
dissection without any preoperative therapy at the Department of
Thoracic Surgery, Kyoto University between January 1, 1987 and
December 31, 1992, were reviewed. P-stage and histological
typing were re-evaluated and determined according to the current
TNM classification (Mountain, 1997) and the current classifica-
tion by World Health Organization (Travis et al, 1999), respect-
ively. One patient was excluded from the study due to
operation-related death, and thus a final total of 162 patients (122
males and 40 females) were evaluated. For all these patients, the
inpatient medical records, chest X-ray films, whole-body CT
films, bone and gallium scanning data and records of surgery were
reviewed without knowledge of the results of immunohistochem-
ical staining. Follow-up of the postoperative clinical course was
conducted by outpatient medical records and by inquiries by tele-
phone or letter. The day of thoracotomy was considered the
starting day for counting postoperative survival days. 
Clinical characteristics of patients 
UFT was administrated to all patients in whom an informed
consent had been taken; UFT was not administrated if not. As a
result, among all 162 patients, UFT (Taiho Pharmaceutical Co,
Tokyo, Japan) was administered to 44 patients (UFT group), and
not administered to the other 118 patients (control group).
Administration dose of UFT was 300 mg day21 body21 (body
weight < 50 kg) or 400 mg day21 body21 (body weight ³50 kg).
Oral administration of UFT was initiated within one month after
surgery. UFT was administered for at least one year if the patients
were alive; for deceased patients, UFT was administered until oral
administration became impossible. There were no significant
differences in clinical characteristics of patients between the UFT
group ant the control group (Table 1). No other preoperative, intra-
operative, or postoperative therapy was performed in any case. 
Tissue preparation 
Detection of apoptotic cells was performed with the terminal
deoxynucleotidyl transferase-mediated dUTP-biotin nick end-
labelling (TUNEL) method. Expression of PCNA (proliferating
cell nuclear antigen), which was expressed in nucleus at the
late G1 phase and S phase of the cell cycle, was examined
immunohistochemically as an index of cell proliferation. Aberrant
expression of p53 and expression of bcl-2 were also examined
immunohistochemically. Serial 4-mm sections were prepared from
each formalin-fixed and paraffin-embedded tumour specimen, and
served for routine haematoxylin and eosin (H&E) staining, the
TUNEL staining and immunohistochemical staining (IHS).
Dewaxed sections were digested with 20 mg ml21 proteinase K
(Boehringer Manheim, Manheim, Germany) for 20 minutes at
25˚C for the TUNEL staining, and were heated in a microwave
oven for 5 minutes three times for IHS. Endogenous peroxidase
was inactivated by incubating the sections with 0.03% H2O2 in
methanol for 30 minutes at 25˚C. To reduce unspecific labelling,
the sections were incubated with normal calf serum (DAKO Japan,
Kyoto, Japan). 
Detection of apoptosis 
The TUNEL staining was performed using In Situ Death
Detection Kit, POD (Boehringer Manheim, Manheim, Germany)
following the manufactured protocol as described previously
(Tanaka et al, 1999b). The specificity of the TUNEL staining of
apoptotic cells was confirmed by making the negative and the
positive control slides at every staining. As negative control slides,
sections incubated with the TUNEL reaction mixture without TdT
were used. As positive control slides, sections treated with DNase
1 (0.7 mg ml–1, Stratgene, La Jolla, CA) for 10 minutes at 25˚C
before the TUNEL reaction were used. Apoptotic cells were deter-
mined with careful observation of TUNEL-staining sections and
serial H&E-staining sections. TUNEL-positive staining cells that
represent histological features of necrosis in H&E-staining
sections were not considered to be apoptotic cells. In each case, a
total of 10 000 tumour cells, 1000 tumour cells each in 10 different
fields, were evaluated at high magnification (3400) by two
authors independently (F.T. and Y.O) without knowledge of clin-
ical data. When a different evaluation of apoptotic cells was made,
the field was re-evaluated until the evaluation coincided. The
apoptotic index (AI) was defined as the number of apoptotic cells
per 1000 tumour cells. 
IHS 
Procedure of IHS using streptoavidin-biotinylated horseradish-
peroxidase complex method (LSAB kit; DAKO JAPAN, Kyoto,
Japan) was described previously (Tanaka et al, 1998b, 1999a,
1999b). Mouse anti-human PCNA, monoclonal antibody (MoAb)
PC-10 (mouse IgG2a, kappa 400 mg ml21 DAKO Japan) diluted at
1:50, anti-human p53 MoAb, clone DO-7 (mouse IgG2b, kappa,
250 mg ml21, DAKO Japan) diluted at 1:50, and anti-human bc1-2
MoAb, clone 124 (mouse IgG, kappa, 200 mg ml21, DAKO Japan)
diluted at 1:50 and mouse were used as the primary antibody.
Stained tissue slides were evaluated by two of the authors (F.T. and
Y.O.) independently without knowledge of clinical data. A total of
1000 tumour cells were counted, and the percentages of positive
cells were determined. When the percentage of positive-staining
cells exceeded 5%, the slide was judged to exhibit aberrant expres-
sion of p53 or positive expression of bcl-2. The fraction of prolif-
erative cells was represented by the percentage of PCNA-positive
tumour cells (proliferative index: PI).
Statistical methods 
Counts were compared by the chi-square test, and trends in counts
were analysed by the chi-square test for trends. Continuous data
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was normal, or using Mann-Whitney U-test if the sample distribu-
tion was asymmetrical. Postoperative survival rate was analysed
by the Kaplan-Meier method, and the difference was assessed by
the log-rank test. Multivariate analysis of prognostic factors was
performed using Cox’s regression model. Differences were consid-
ered significant when P- value was less than 0.05. All statistical
manipulations were performed using the SPSS for Windows soft-
ware system (SPSS Inc, Chicago, IL, USA, 1993). 
RESULTS 
Incidence of apoptosis (AI), aberrant expression of p53
and expression of bcl-2
The mean AI for all patients was 19.2 ± 2.0 (mean ± standard
error: SE), and the median AI was 10.9. There was no difference 
in the mean AI between the UFT group and the Control group 
(Table 1). Even if the patients were divided to patients with higher
AI (AI ³ 10.9) and those with lower AI (AI < 10.9), there was no
difference in ratios of higher and lower AI patients between the
UFT group and the Control group. In 67 of 162 (41.4%) patients,
p53 aberrant expression was demonstrated. In only 33 (20.4%)
patients, bcl-2 was expressed. There was no significant difference
in ratios of patients with p53 aberrant expression or in ratios of
bcl-2-positive patients between the UFT group and the Control
group (Table 1). 
Correlation of AI with cell proliferation, aberrant
expression of p53 and expression of bcl-2
Correlation between AI and fraction of proliferative cancer cells
(PI) was examined (Table 2). The mean PI in higher-AI patients
was 53.5%, which was significantly higher than that in lower-AI
patients (31.6%). Moreover, the number of patients showing
higher PI (PI ³ 44%) was larger in higher-AI patients than in
lower-AI patients. These results demonstrated that more cancer
cells showing active proliferation have more chances of under-
going apoptosis. On the other hand, no significant correlation of
AI with p53 aberrant expression or bcl-2 expression was observed. 
AI, aberrant expression of p53 expression of bcl-2 and
postoperative prognosis 
According to univariate analysis of prognostic factors, 5-year
survival rates of patients with and those without p53 aberrant
expression were 60.4% and 80.1%, suggesting p53 aberrant
expression was a significant factor to predict poor prognosis (P =
0.011). In contrast, no significant difference was observed in the
prognosis between patients with and those without bcl-2 expres-
sion, or between patients with higher AI and those with lower AI
(Table 3). Multivariate analysis also confirmed that p53 aberrant
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Table 1 Characteristics of patients, apoptotic index (AI) and apoptosis-related gene (p53, bcl-2) status in patients with and without postoperative oral
administration of UFT 
All patients Patients with Patients without  P valuea
UFT administration UFT administration
Gender Male 122 (75.3%) 31 (70.5%) 91 (77.1%)  0.382 
Female 40 (24.7%) 13 (29.5%) 27 (22.9%)
Age (mean, years) 62.7 61.8 63.0 0.460 
Performance status 0 147 (90.7%) 40 (90.9%) 107 (90.7%) 0.755 
1 15 (9.3%) 4 (9.1%) 11 (9.3%)
Pathologic T1 (stage IA) 84 (51.9%) 23 (52.3%) 61 (51.7%) 0.948 
T2 (stage IB) 78 (48.1%) 21 (47.7%) 57 (48.3%) 
Histology Squamous cell 55 (34.0%) 14 (31.8%) 41 (34.7%)
Adenocarcinoma 93 (57.4%) 27 (61.4%) 66 (55.9%)  0.713 
Large cell 11 (6.8%) 2 (4.5%) 9 (7.6%)
Others 3 1 2
Apoptotic index (AI, mean) 19.2/1000 cancer cells 20.8 18.6 0.637 
Lower-AI (<10.9) 81 (50.0%) 23 (52.3%) 58 (49.2%) 0.724 
Higher-AI (³10.9) 81 (50.0%) 21 (47.7%) 60 (50.8%)
p53 aberrant expression
Negative 95 (58.6%) 25 (56.8%) 70 (59.3%) 0.773 
Positive 67 (41.4%) 19 (43.2%) 48 (40.7%)
bcl-2 expression
Negative 129 (79.6%) 32 (72.7%) 97 (82.2%) 0.183 
Positive 33 (20.4%) 12 (27.3%) 21 (17.8%)
aP value: Comparison of patients’ characteristics between patients with and without postoperative administration of UFT.
Table 2 Correlation between apoptotic index (AI) and apoptosis-related
gene (p53, bcl-2) status 
Lower-AIb Higher-AIb P valuea
Proliferative index (PI, mean) 31.6% 53.5% <0.001 
Lower-PIc 58 (71.6%) 24 (29.6%) <0.001 
Higher-PIc 23 (28.4%) 57 (70.4%)
p-53 aberrant expression 
Negative 50 (61.7%) 45 (55.6%) 0.425 
Positive 31 (38.3%) 36 (44.4%)
bcl-2 expression 
Negative 62 (76.5%) 67 (82.7%) 0.329 
Positive 19 (23.5%) 14 (17.3%)
aP value: Comparison of patients’ characteristics between patients with 
Lower-AI and those with Higher-AI. bLower-AI: AI < 10.9 (median AI).
Higher-AI: AI ³ 10.9 (median AI). cLower-PI: PI < 44% (median PI). Higher-
PI: PI ³ 44% (median PI). expression was a significant factor to predict poor postoperative,
and that bcl-2 expression or AI could not be a significant 
prognostic factor (Table 4). 
Efficacy of postoperative UFT administration and AI,
aberrant expression of p53 and expression of bcl-2
5-year survival rates of the UFT group and the Control group were
79.9% and 69.8%, respectively. Although the UFT group seemed
to show favourable prognosis as compared with the Control group,
the difference proved not be significant (P = 0.054, Figure 1). 
The efficacy of the UFT administration was compared between
patients without and those with p53 aberrant expression. In
patients without p53 aberrant expression, the UFT group showed
significantly better prognosis than the Control group (95.2% and
74.3%, respectively, P = 0.022, Figure 2a), demonstrating that
UFT administration could improve the postoperative prognosis. In
patients with p53 aberrant expression, however, there was no
significant difference in the prognosis between the UFT group and
the Control group (55.8% and 62.8%, respectively, P = 0.834,
Figure 2b), demonstrating that UFT administration was not effect-
ive in such cases. In contrast, there was no difference demon-
strated in the efficacy of the UFT administration between patients
with bcl-2 expression and those without bcl-2 expression, showing
the efficacy of UFT was not influenced by the status of bcl-2
(Table 5). 
Concerning AI and the efficacy of UFT, in patients with lower AI,
there was no significant difference in the prognosis between the
UFT group and the Control group (5-year survival rates: 74.6% and
71.6%, respectively, P = 0.592, Figure 3a), showing that UFT
administration was not effective in lower-AI patients. On the other
hand, in patients with higher AI, the UFT group showed signific-
antly better prognosis than the Control group (5-year survival rates:
83.3% and 67.6%, respectively, P = 0.039, Figure 3b), suggesting
that UFT administration was effective in higher-AI patients. 
To confirm the efficacy of UFT administration in patients
without p53 expression and those with higher AI, multivariate
analysis was performed among each patient-group. As a result,
UFT administration proved to be an independent prognostic factor
to improve the prognosis among patients without p53 aberrant
expression (P = 0.030, relative risk (RR) and the 95% confidence
interval (CI): 0.094 (0.011–0.799)), whereas not among patients
with p53 aberrant expression (P = 0.830, RR and the 95% CI:
1.107 (0.439–2.787)). Similarly, UFT administration proved to be
an independent prognostic factor to improve the prognosis among
higher-AI (P = 0.032, RR and the 95% CI: 0.255 (0.068–0.900)),
whereas not among lower-AI patients (P = 0.311, RR and the 95%
CI: 0.599 (0.214–1.635)). 
DISCUSSION 
In the present study, it was suggested that efficacy of UFT admin-
istration as a postoperative adjuvant therapy for NSCLC might be
influenced by incidence of apoptosis (AI) and status of p53
regulating apoptosis. UFT is a 5-FU derivative chemotherapeutic
agent developed in Japan, and has been widely used in Japan
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Table 3 Unvariate analysis of prognostic factors 
Prognostic factors 5-year survival rate P value 
Gender 
Male/Female 66.9%/82.7% 0.467
Agea
Lower age / Higher age 76.3%/64.7% 0.086
Performance Status 
0 / 1 72.0%/46.2% 0.124
Pathologic-T factor 
T1 (IA) / T2 (IB) 71.9%/69.4% 0.758
Histology 
Squamous cell / Adenocarcinoma 67.9%/73.1% 0.909
p53 aberrant expression 
Negative / Positive 80.1%/60.4% 0.011
bcl-2 expression 
Negative / Positive 71.2%/75.9% 0.349
Apoptotic index (AI)b
Lower / Higher 72.1%/71.5% 0.684
Proliferative index (PI)c
Lower/Higher 74.0% / 75.6% 0.261
Postoperative UFT administration 
No / Yes 79.9% / 69.8% 0.054
aLower age: Age < 64.0 years (median age). Higher age: Age ³ 64.0 years 
(median age). bLower-AI: AI < 10.9 (median AI). Higher-AI: AI ³ 10.9
(median AI). cLower-PI: PI < 44% (median PI). Higher-PI: PI ³ 44% (median
PI). 
Table 4 Multivariate analysis of prognostic factors (Cox’s proportional hazard model) 
Prognostic factors b P value Relative hazard (95% confidence interval) 
Gender (Male/Female) 0.049 0.915 1.050 (0.432–2.550) 
Age 0.023 0.276 1.023 (0.982–1.065) 
Performance status (0/1) 0.528 0.256 1.695 (0.682–4.211) 
Pathologic-T factor (1/2) 0.084 0.818 1.088 (0.532–2.224) 
Histology (Adenocarcinoma or not) 0.454 0.254 1.575 (0.723–3.435) 
p53 aberrant expression 
(Negative/Positive) 0.983 0.008 2.673 (1.290–5.539) 
bcl-2 expression 
(Negative/Positive) 0.292 0.531 1.340 (0.537–3.345) 
Apoptotic index (AI)a
(Lower/Higher) 0.509 0.186 1.663 (0.782–3.540) 
Proliferative index (PI)b
(Lower/Higher) 20.748 0.054 0.473 (0.221–1.013) 
Postoperative UFT (2/+) 21.220 0.012 0.295 (0.115–0.761) 
aLower-AI: AI < 10.9 (median AI). Higher-AI: AI ³ 10.9 (median AI). bLower-PI: PI < 44% (median PI). Higher-PI: PI ³ 44% (median PI). mainly for malignant tumours originating from the digestive
system. Recently, UFT has been introduced to clinical trials
conducted in the United States. Pazdur and coworkers have
already reported that UFT is effective to metastatic colorectal
cancer when administrated with leucovorin (Pazdur et al, 1994).
Although 5-FU has been used as a basic chemotherapeutic agent
for a variety of solid tumours, it has been reported that 5-FU is not
effective to primary lung cancer. However, all these reports are
based on results obtained by an intravenous bolus injection. Many
experimental and clinical studies have revealed that 5-FU is 
not a dose-dependent but a time-dependent agent (Pinedo
and Peter, 1988; Lokich et al, 1989). Oral administration of 5-
FU and the derivatives which can continuously maintain 5-FU
concentration is an extremely useful method when the pharmaco-
logical features of 5-FU are considered (Fujii et al, 1978; Ikenaka
et al, 1979). 
UFT is inferior to other chemotherapeutic agents such as CDDP
in terms of potency of direct anticancer activity. However, these
chemotherapeutic agents with potent antitumour effect have not
improved postoperative survival of NSCLC. The most important
factor that worsens the prognosis of completely resected NSCLC
patients is high incidence of distant metastasis after operation.
Recently, it has been revealed experimentally that tumour growth
was suppressed with induction of apoptosis in micrometastatic
lesion (Holmgren et al, 1995). We have also revealed clinically
that the balance of apoptosis and proliferation of cancer cells influ-
ences on postoperative survival of NSCLC (Tanaka et al, 1999b).
Postoperative oral administration of UFT maintains a certain blood
concentration of 5-FU, which may accelerate apoptosis of cancer
cells in micrometastatic lesions without suppression of patients’
immunity, resulting in improving the postoperative prognosis.
Association of the efficacy of UFT with apoptosis is supported by
the results obtained in the present study. In patients with higher AI,
that is patients whose cancer cells can be easily induced to
apoptotic death without treatment, UFT is effective as postopera-
tive administration of UFT can suppress recurrence by acceler-
ating apoptosis of cancer cells. On the other hand, in patients with
lower AI, that is patients whose cancer cells can not be easily
induced to apoptotic death, UFT administration can not regulate
micrometastases by failure to induce such cancer cells to apop-
tosis. This speculation is consistent with results of basic experi-
ments demonstrating that many anticancer drugs such as CDDP
and 5-FU induce cancer cells to apoptosis (Sen and D’Incaki,
1992). 
The p53 gene is an important gene that regulates apoptosis. It
has been demonstrated experimentally and clinically that the anti-
tumour effect of chemotherapeutic agents was remarkably
decreased if the p53 gene is mutated (Fujiwara et al, 1994; Lowe 
et al, 1994; Bergh et al, 1995). These results are consistent with
our results demonstrating that the efficacy of postoperative oral
administration of UFT was diminished in patients with aberrant
expression of p53, and are reasonably understandable when the
function of p53 gene and apoptosis are considered. IHS employed
in the present study to determine p53 status is clinically useful,
because it is very easy and inexpensive as well as it can be
performed on paraffin-embedded slides. However, accurate detec-
tion of p53 gene mutation can be achieved only when a complete
sequence of the p53 gene is determined (Carbone et al, 1994). In
future study, correlation between efficacy of UFT and the presence
of p53 gene mutation should be examined. 
The bcl-2 gene was cloned as a gene that prolongs a cellular
life by inhibiting apoptosis. Although there has been many
reports on significance of bcl-2 expression in NSCLC, a definite
conclusion has not yet been established (Pezzella et al, 1993;
Pastorino et al, 1997). Because the incidence of bcl-2 expression
in NSCLC is as low as about 20%, the significance of bcl-2
expression as a prognostic factor and a predictive factor of thera-
peutic effect may not be important. In future, to clarify signifi-
cance of p53 aberrant expression detected with IHS and
incidence of apoptosis (AI) in association with the efficacy of
postoperative oral administration of UFT, prospective random-
ized study on the UFT administration stratified by the p53 status
and AI should be conducted. 
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UFT administration (+)
5-year survival rate:   79.9%
5-year survival rate: 69.8%
UFT administration (–)
P = 0.054 (log-rank test)
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Figure 1 Survival after complete tumour resection with lymph node
dissection for p-stage I, non-small cell lung cancer (NSCLC). Comparison
between patients with postoperative UFT administration and those without
postoperative UFT administration 
Table 5 Postoperative survival and influence of UFT administration 
5-year survival rate (%) 
Patients with UFT  Patients without  P valuea
administration UFT administration
All patients 79.9 69.8 0.054 
Stratified by apoptosis 
and apoptosis-related 
gene status
Apoptosis index (AI)b
Lower-AI 74.6 71.6 0.592 
Higher-AI 83.3 67.6 0.039 
p53 status 
Aberrant expression:  95.2 74.3 0.022 
negative
Aberrant expression:  55.8 62.8 0.834 
positive
bcl-2 status 
Expression: negative 78.5 68.8 0.089 
Expression: positive 78.8 75.2 0.873 
aP-value: Comparison of patients’ characteristics between patients with and
without postoperative administration of UFT. bLower-AI: AI < 10.9 (median
AI). Higher-AI: AI ³ 10.9 (median AI).ACKNOWLEDGEMENT 
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Figure 3 (A) Postoperative survival of patients demonstrating lower apoptotic index (AI). Comparison between patients with postoperative UFT administration
and those without postoperative UFT administration. (B) Postoperative survival of patients demonstrating higher apoptotic index (AI). Comparison between
patients with postoperative UFT administration and those without postoperative UFT administration
UFT administration (+)
5-year survival rate: 74.6%
5-year survival rate: 71.6%
UFT administration (–)
P = 0.592 log-rank test)
012345
Years after operation
0.0
0.2
0.4
0.6
0.8
1.0
S
u
r
v
i
v
a
l
(A) UFT administration (+)
5-year survival rate: 83.3%
5-year survival rate: 67.6%
UFT administration (–)
P = 0.039 (log-rank test)
012345
Years after operation
0.0
0.2
0.4
0.6
0.8
1.0
S
u
r
v
i
v
a
l
(B)
UFT administration (+)
5-year survival rate: 95.2%
5-year survival rate: 74.3%
UFT administration (–)
P = 0.022 (log-rank test)
012345
Years after operation
0.0
0.2
0.4
0.6
0.8
1.0
S
u
r
v
i
v
a
l
(A)
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